Arrowhead Pharmaceuticals Inc (LTS:0HI3)
$ 24.91 0.9324 (3.89%) Market Cap: 3.17 Bil Enterprise Value: 2.76 Bil PE Ratio: 0 PB Ratio: 6.54 GF Score: 51/100

Arrowhead Pharmaceuticals Inc Key Opinion Leader Webinar on ARO-ENaC Transcript

Jul 28, 2020 / 04:00PM GMT
Release Date Price: $47.73
Operator

(technical difficulty)

All in the event. I would now like to turn the call over to your host, Vince Anzalone, Vice President of Investor Relations at Arrowhead Pharmaceuticals. Please go ahead, sir.

(technical difficulty)

Vincent Anzalone
Arrowhead Pharmaceuticals, Inc. - VP of IR

Okay. Thanks so much, and sorry for the delay. Sara, if you can switch to the next slide. Okay, and thanks, everybody. Before we start, I just want to remind you that we will be making forward-looking statements on today's presentation. So please refer to risk factors in our regulatory filings.

Next slide, please. Next slide. So we are very lucky today to have a great panel to talk about ENaC, our first pulmonary TRIM-enabled candidate targeting cystic fibrosis. And the key opinion leader that we have joining us today is Dr. Marcus Mall, who is the Professor and Director of the Department of Pediatric Pulmonology and Immunology at the Charité University Medical Center in Berlin. He is a world expert in CF and on alternative target to CF like, such as

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot